• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Accuracy of ultrasound and noninvasive markers of fibrosis to identify patients with cirrhosis.超声及纤维化无创标志物用于识别肝硬化患者的准确性。
Dig Dis Sci. 2015 Jun;60(6):1841-7. doi: 10.1007/s10620-015-3531-1. Epub 2015 Jan 14.
2
Can transient elastography, Fib-4, Forns Index, and Lok Score predict esophageal varices in HCV-related cirrhotic patients?瞬时弹性成像、Fib-4指数、Forns指数和Lok评分能否预测丙型肝炎病毒相关肝硬化患者的食管静脉曲张?
Gastroenterol Hepatol. 2014 Feb;37(2):58-65. doi: 10.1016/j.gastrohep.2013.09.008. Epub 2013 Dec 21.
3
Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis.天门冬氨酸氨基转移酶-血小板比值指数对丙型肝炎相关纤维化分期的诊断效能:一项更新的荟萃分析。
Hepatology. 2011 Mar;53(3):726-36. doi: 10.1002/hep.24105. Epub 2011 Feb 11.
4
Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients.验证 FIB-4 并与其他简单的无创指标比较,以预测乙型肝炎病毒感染患者的肝纤维化和肝硬化。
Liver Int. 2010 Apr;30(4):546-53. doi: 10.1111/j.1478-3231.2009.02192.x. Epub 2010 Jan 13.
5
APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B.APRI、FIB-4评分和福尔恩指数对慢性乙型肝炎患者的肝纤维化具有无创诊断价值。
Eur J Gastroenterol Hepatol. 2013 Sep;25(9):1076-81. doi: 10.1097/MEG.0b013e32835fd699.
6
Serum Biomarkers Predictive of Significant Fibrosis and Cirrhosis in Chronic Hepatitis B.预测慢性乙型肝炎显著纤维化和肝硬化的血清生物标志物
J Clin Gastroenterol. 2015 Sep;49(8):705-13. doi: 10.1097/MCG.0000000000000250.
7
Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease.天门冬氨酸氨基转移酶与血小板比值及纤维化-4 作为肝活检证实的儿童囊性纤维化肝病的生物标志物。
Hepatology. 2015 Nov;62(5):1576-83. doi: 10.1002/hep.28016. Epub 2015 Sep 28.
8
The diagnostic accuracy of the Forns index, platelet count and AST to Platelet Ratio Index derived fibrosis index for the prediction of Hepatitis C virus-related significant liver fibrosis and cirrhosis.Forns指数、血小板计数及AST与血小板比值指数衍生纤维化指数对丙型肝炎病毒相关显著肝纤维化和肝硬化预测的诊断准确性。
Scand J Clin Lab Invest. 2014 Apr;74(3):240-7. doi: 10.3109/00365513.2013.879392. Epub 2014 Jan 24.
9
Magnetic resonance elastography and biomarkers to assess fibrosis from recurrent hepatitis C in liver transplant recipients.磁共振弹性成像和生物标志物评估肝移植受者丙型肝炎复发引起的纤维化。
Transplantation. 2011 Sep 15;92(5):581-6. doi: 10.1097/TP.0b013e31822805fa.
10
[Ultrasonic scores combined with blood indexes for screening and predicting compensated liver cirrhosis in chronic hepatitis B patients].[超声评分联合血液指标用于慢性乙型肝炎患者代偿期肝硬化的筛查与预测]
Nan Fang Yi Ke Da Xue Xue Bao. 2008 Dec;28(12):2157-60.

引用本文的文献

1
[Not Available].[无可用内容]
Adv Lab Med. 2024 Feb 14;5(2):131-147. doi: 10.1515/almed-2023-0172. eCollection 2024 Jun.
2
Serum biomarkers for liver fibrosis assessment.用于肝纤维化评估的血清生物标志物。
Adv Lab Med. 2023 Nov 14;5(2):115-130. doi: 10.1515/almed-2023-0081. eCollection 2024 Jun.
3
Assessing the Utility of the Aspartate Aminotransferase to Platelet Ratio Index (APRI) as a Noninvasive Indicator for Liver Cirrhosis.评估天冬氨酸氨基转移酶与血小板比值指数(APRI)作为肝硬化无创指标的效用。
Cureus. 2024 May 5;16(5):e59680. doi: 10.7759/cureus.59680. eCollection 2024 May.
4
Sex-specific changes in triglyceride profiles in liver cirrhosis and hepatitis C virus infection.肝硬化和丙型肝炎病毒感染患者中甘油三酯谱的性别特异性变化。
Lipids Health Dis. 2022 Oct 24;21(1):106. doi: 10.1186/s12944-022-01715-w.
5
Estimation of hepatocellular carcinoma mortality using aspartate aminotransferase to platelet ratio index.利用天冬氨酸转氨酶与血小板比值指数估算肝细胞癌死亡率。
J Gastrointest Oncol. 2020 Apr;11(2):291-297. doi: 10.21037/jgo.2018.11.01.
6
Chronic Rifaximin Use in Cirrhotic Patients Is Associated with Decreased Rate of C. difficile Infection.肝硬化患者长期使用利福昔明与艰难梭菌感染率降低相关。
Dig Dis Sci. 2020 Feb;65(2):632-638. doi: 10.1007/s10620-019-05804-2. Epub 2019 Aug 22.
7
Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status.肝硬化而非抗病毒治疗可预测具有不同乙型肝炎病毒状态的队列的临床结局。
Gut Liver. 2019 Mar 15;13(2):197-205. doi: 10.5009/gnl18204.
8
Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C.瞬时弹性成像- FibroScan®、声辐射力脉冲(ARFI)成像、增强型肝脏纤维化(ELF)检测、APRI 和 FIB-4 指数与慢性丙型肝炎患者肝活检的比较。
Clinics (Sao Paulo). 2017 Oct;72(9):516-525. doi: 10.6061/clinics/2017(09)01.
9
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.非酒精性脂肪性肝炎临床试验终点纳入和分析的定义:从监管科学的角度。
Hepatology. 2018 May;67(5):2001-2012. doi: 10.1002/hep.29607. Epub 2018 Feb 22.
10
Diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index and liver stiffness measurement in hepatitis B virus-infected patients with persistently normal alanine aminotransferase.在丙型肝炎病毒感染持续正常丙氨酸氨基转移酶患者中,FIB-4、天门冬氨酸氨基转移酶与血小板比值指数和肝硬度测量的诊断价值。
World J Gastroenterol. 2017 Aug 21;23(31):5746-5754. doi: 10.3748/wjg.v23.i31.5746.

本文引用的文献

1
Non-invasive diagnosis of advanced fibrosis and cirrhosis.晚期纤维化和肝硬化的非侵入性诊断
World J Gastroenterol. 2014 Dec 7;20(45):16820-30. doi: 10.3748/wjg.v20.i45.16820.
2
Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis.基层医疗服务提供者的实践模式与态度以及肝硬化患者肝细胞癌监测的障碍
Clin Gastroenterol Hepatol. 2015 Apr;13(4):791-8.e1. doi: 10.1016/j.cgh.2014.06.031. Epub 2014 Jul 11.
3
Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.肝硬化患者肝细胞癌监测的早期检测、治愈治疗和生存率:一项荟萃分析。
PLoS Med. 2014 Apr 1;11(4):e1001624. doi: 10.1371/journal.pmed.1001624. eCollection 2014 Apr.
4
Magnetic resonance imaging in cirrhosis: what's new?肝硬化的磁共振成像:有哪些新进展?
Top Magn Reson Imaging. 2014 Apr;23(2):129-49. doi: 10.1097/RMR.0000000000000017.
5
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?在 HALT-C 试验中,晚期肝细胞癌患者的检测:监测在哪里失败了?
Am J Gastroenterol. 2013 Mar;108(3):425-32. doi: 10.1038/ajg.2012.449. Epub 2013 Jan 22.
6
Failure rates in the hepatocellular carcinoma surveillance process.肝癌监测过程中的失败率。
Cancer Prev Res (Phila). 2012 Sep;5(9):1124-30. doi: 10.1158/1940-6207.CAPR-12-0046. Epub 2012 Jul 30.
7
Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B.前瞻性验证 FibroTest 与肝硬度检测在预测亚洲慢性乙型肝炎患者肝纤维化方面的比较。
PLoS One. 2012;7(4):e35825. doi: 10.1371/journal.pone.0035825. Epub 2012 Apr 20.
8
Safety and effectiveness of blind percutaneous liver biopsy: analysis of 1412 procedures.盲目经皮肝穿刺活检的安全性与有效性:1412例操作分析
Hepat Mon. 2012 Jan;12(1):32-7. doi: 10.5812/kowsar.1735143x.4388. Epub 2012 Jan 20.
9
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis.肝硬化患者肝癌监测的效果。
Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):793-9. doi: 10.1158/1055-9965.EPI-11-1005. Epub 2012 Feb 28.
10
Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review.美国患者肝癌监测的利用情况:系统评价。
J Gen Intern Med. 2012 Jul;27(7):861-7. doi: 10.1007/s11606-011-1952-x. Epub 2012 Jan 4.

超声及纤维化无创标志物用于识别肝硬化患者的准确性。

Accuracy of ultrasound and noninvasive markers of fibrosis to identify patients with cirrhosis.

作者信息

Martin Jason, Khatri Gaurav, Gopal Purva, Singal Amit G

机构信息

Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System, Dallas, TX, USA.

出版信息

Dig Dis Sci. 2015 Jun;60(6):1841-7. doi: 10.1007/s10620-015-3531-1. Epub 2015 Jan 14.

DOI:10.1007/s10620-015-3531-1
PMID:25586089
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4456228/
Abstract

BACKGROUND

Accurate identification of patients with cirrhosis using noninvasive markers of fibrosis is useful for esophageal varices and hepatocellular carcinoma surveillance programs. The aims of our study were to characterize the accuracy of ultrasonography, AST-to-platelet ratio index (APRI), and FIB-4 as noninvasive markers to identify the presence of cirrhosis.

METHODS

We conducted a retrospective cohort study of patients who underwent liver biopsy at a large urban safety-net institution between November 2008 and July 2011. The sensitivity, specificity, positive predictive value (PPV), negative predictive value, and overall accuracy using receiver operator characteristic curve analysis for the detection of cirrhosis were calculated for each noninvasive marker.

RESULTS

Liver biopsy was performed in 388 patients, of whom 93 (24.0 %) had cirrhosis. C-statistics for APRI and FIB-4 predicting the presence of cirrhosis were 0.68 (95 % CI 0.63-0.74) and 0.73 (95 % CI 0.68-0.78), respectively. The c-statistic for a nodular appearance on ultrasound was 0.78 (95 % CI 0.72-0.83). The PPV of a shrunken nodular-appearing liver was 64.8 %; however, PPV was significantly higher in the subset with a cirrhotic-appearing liver and signs of portal hypertension (PPV 83.6 %, p = 0.01) as well as in the subset with a noninvasive fibrosis marker also suggesting cirrhosis (PPV 77.8 %, p < 0.001).

CONCLUSION

Serum and imaging noninvasive markers of fibrosis may have insufficient accuracy when used in isolation; however, a combination of markers may allow sufficient accuracy to systematically identify patients with cirrhosis.

摘要

背景

使用纤维化的非侵入性标志物准确识别肝硬化患者,对于食管静脉曲张和肝细胞癌监测计划很有用。我们研究的目的是将超声、AST与血小板比值指数(APRI)和FIB-4作为非侵入性标志物识别肝硬化存在的准确性进行特征描述。

方法

我们对2008年11月至2011年7月期间在一家大型城市安全网机构接受肝活检的患者进行了一项回顾性队列研究。针对每种非侵入性标志物,使用受试者操作特征曲线分析计算检测肝硬化的敏感性、特异性、阳性预测值(PPV)、阴性预测值和总体准确性。

结果

388例患者接受了肝活检,其中93例(24.0%)患有肝硬化。APRI和FIB-4预测肝硬化存在的C统计量分别为0.68(95%CI 0.63 - 0.74)和0.73(95%CI 0.68 - 0.78)。超声检查出现结节样外观的C统计量为0.78(95%CI 0.72 - 0.83)。肝脏呈萎缩结节样外观的PPV为64.8%;然而,在具有肝硬化样外观和门静脉高压体征的亚组中PPV显著更高(PPV 83.6%,p = 0.01),以及在非侵入性纤维化标志物也提示肝硬化的亚组中PPV也显著更高(PPV 77.8%,p < 0.001)。

结论

单独使用时,血清和影像学纤维化非侵入性标志物的准确性可能不足;然而,标志物组合可能具有足够的准确性来系统地识别肝硬化患者。